First Trust Advisors
SPRY icon

First Trust Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

First Trust Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-422,038
Closed -$3.39M – 2745
2026
Q1 		$3.39M Buy
+422,038
New +$4.04M ﹤0.01% 1676
2025
Q4 		– Sell
-352,943
Closed -$3.55M – 2710
2025
Q3 		$3.55M Buy
352,943
+12,824
+4% +$184K ﹤0.01% 1554
2025
Q2 		$5.94M Buy
+340,119
New +$4.91M ﹤0.01% 1278

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors's SPRY Position: Q2 2026 in Review

First Trust Advisors sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 422,038 shares — an estimated $3.39M sold.

First Trust Advisors first reported a position in SPRY in Q2 2025 and held it in 3 quarters. The position peaked at $5.94M in Q2 2025. 139 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • First Trust Advisors reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • First Trust Advisors sold 422,038 ARS Pharmaceuticals shares in Q2 2026, an estimated $3.39M.
  • First Trust Advisors first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • First Trust Advisors's ARS Pharmaceuticals position peaked at $5.94M in Q2 2025.
  • 139 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.